Taken together, our data showed an increased PRAME antigen-specific CTL cytotoxicity targeting AML cells after treatment with subtype selective HDAC inhibitor chidamide alone or in combination with hypomethylating agent decitabine in vitro, through mechanisms including the upregulation of PRAME and CD86 in AML cells. Here, HDAC9 is linked to acute myeloid leukemia.